ArticleBMC nephrology2026
Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany.
Isabell Kaufhold et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.